Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma

被引：0
|
作者：
Xu, N. [1 ]
Han, B. [2 ]
Jiao, S. [3 ]
Hu, C. [4 ]
Mislang, A. [5 ]
Coward, J. [6 ]
Cooper, A. [7 ]
Underhill, C. [8 ]
Xia, Y. [9 ]
Xia, D. [9 ]
Jin, X. [9 ]
Wang, Z. M. [9 ]
Li, B. [9 ]
机构：
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Oncol, Hangzhou, Peoples R China
[2] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China
[4] Shanghai Canc Ctr, Dept Radiotherapy, Shanghai, Peoples R China
[5] Adelaide Canc Ctr, Dept Oncol, Kurralta Pk, Australia
[6] Icon Canc Ctr, Dept Oncol, Brisbane, Qld, Australia
[7] Univ Western Sydney, Sch Med, Dept Oncol, Liverpool, Australia
[8] Albury Wodonga Reg Canc Ctr, Dept Oncol, Albury, NSW, Australia
[9] Akeso Biopharma Inc, Zhongshan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.518
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
31P
引用
收藏
页码：S1428 / S1429
页数：2
相关论文
共 50 条
  • [41] The path forward for anti-programmed cell death-1 therapy in gliomas
    Majd, Nazanin
    Kamiya-Matsuoka, Carlos
    de Groot, John
    CURRENT OPINION IN NEUROLOGY, 2019, 32 (06) : 864 - 871
  • [42] Intracorneal pustular drug eruption, a novel cutaneous adverse event in anti-programmed cell death-1 patients that highlights the effect of anti-programmed cell death-1 in neutrophils
    Zhao, Cathy Yunjia
    Consuegra, Germana
    Chou, Shaun
    Fernandez-Penas, Pablo
    MELANOMA RESEARCH, 2017, 27 (06) : 641 - 644
  • [43] Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients
    Cybulska-Stopa, Bozena
    Zietek, Marcin
    Kaminska-Winciorek, Grazyna
    Czarnecka, Anna M.
    Piejko, Karolina
    Galus, Lukasz
    Ziolkowska, Barbara
    Kieszko, Stanislaw
    Kempa-Kaminska, Natasza
    Calik, Jacek
    Zemelka, Tomasz
    Kubiatowski, Tomasz
    Suwinski, Rafal
    Mackiewicz, Jacek
    Rutkowski, Piotr
    MELANOMA RESEARCH, 2021, 31 (01) : 49 - 57
  • [44] Anti-Programmed Death 1 (PD-1) Antibodies and the Pancreas: A Diabetic Storm Ahead?
    Marchand, Lucien
    Thivolet, Arnaud
    Saintigny, Pierre
    Fabien, Nicole
    Vouillarmet, Julien
    Thivolet, Charles
    DIABETES CARE, 2018, 41 (03) : 638 - 639
  • [45] Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
    Liang, Jiaqi
    Li, Ming
    Sui, Qihai
    Hu, Zhengyang
    Bian, Yunyi
    Huang, Yiwei
    Zhan, Cheng
    Jiang, Wei
    Wang, Qun
    Tan, Lijie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1302 - +
  • [46] Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients
    Valentine Heidelberger
    François Goldwasser
    Nora Kramkimel
    Anne Jouinot
    Nathalie Franck
    Jennifer Arrondeau
    Sarah Guégan
    Audrey Mansuet-Lupo
    Jérôme Alexandre
    Diane Damotte
    Marie-Françoise Avril
    Nicolas Dupin
    Sélim Aractingi
    Investigational New Drugs, 2017, 35 : 842 - 847
  • [47] Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients
    Heidelberger, Valentine
    Goldwasser, Francois
    Kramkimel, Nora
    Jouinot, Anne
    Franck, Nathalie
    Arrondeau, Jennifer
    Guegan, Sarah
    Mansuet-Lupo, Audrey
    Alexandre, Jerome
    Damotte, Diane
    Avril, Marie-Francoise
    Dupin, Nicolas
    Aractingi, Selim
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (06) : 842 - 847
  • [48] Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)
    Rizvi, Naiyer A.
    Gettinger, Scott N.
    Goldman, Jonathan W.
    Hellmann, Matthew D.
    Chow, Laura Q.
    Juergens, Rosalyn
    Borghaei, Hossein
    Brahmer, Julie R.
    Shen, Yun
    Harbison, Christopher
    Nathan, Faith
    Ready, Neal
    Antonia, Scott J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S176 - S176
  • [49] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
    Naidoo, Jarushka
    Wang, Xuan
    Woo, Kaitlin M.
    Iyriboz, Tunc
    Halpenny, Darragh
    Cunningham, Jane
    Chaft, Jamie E.
    Segal, Neil H.
    Callahan, Margaret K.
    Lesokhin, Alexander M.
    Rosenberg, Jonathan
    Voss, Martin H.
    Rudin, Charles M.
    Rizvi, Hira
    Hou, Xue
    Rodriguez, Katherine
    Albano, Melanie
    Gordon, Ruth-Ann
    Leduc, Charles
    Rekhtman, Natasha
    Harris, Bianca
    Menzies, Alexander M.
    Guminski, Alexander D.
    Carlino, Matteo S.
    Kong, Benjamin Y.
    Wolchok, Jedd D.
    Postow, Michael A.
    Long, Georgina V.
    Hellmann, Matthew D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 709 - +
  • [50] Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody
    Liu, Gang
    Zhou, Wenxuan
    Li, Xiaoli
    Guo, Lijie
    He, Tingting
    Zhao, Juan
    Gong, Liansheng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
12345